NEW YORK (GenomeWeb News) – CombiMatrix today said that preliminary revenues for the third quarter was up 15 percent year over year, driven by increased microarray testing volumes.

The Irvine, Calif.-based firm said that for the three months ended Sept. 30, total revenues are expected to be $1.5 million, compared to $1.3 million a year ago, as microarray testing volumes rose to 1,145 billable tests from 857 billable tests a year ago, a 34 percent increase.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.